Elitek Generic Name & Formulations
Rasburicase (recombinant) 1.5mg, 7.5mg; per vial; lyophilized pwd for IV infusion after reconstitution and dilution; contains mannitol.
Single-dose vials 1.5mg—3 (w. diluent); 7.5mg—1 (w. diluent)
Single course treatment for initial management of plasma uric acid levels in patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.
Elitek Dosage and Administration
Adults and Children
Give by IV infusion over 30 mins. 0.2mg/kg daily for 5 days. Dosing >5 days or more than one course of treatment: not recommended.
History of anaphylaxis, or development of hemolytic reactions or methemoglobinemia to rasburicase. G6PD deficiency.
Elitek Boxed Warnings
Anaphylaxis. Hemolysis. Methemoglobinemia. Interference with uric acid measurements.
Discontinue permanently if serious hypersensitivity reactions (including anaphylaxis), hemolysis, or methemoglobinemia develops. Screen high risk patients (eg, African or Mediterranean ancestry) for G6PD deficiency prior to initiation. Pregnancy. Nursing mothers: not recommended (during and for 2 weeks after the last dose).
Interferes with uric acid measurements in blood samples left at room temperature.
Elitek Adverse Reactions
GI upset, pyrexia, peripheral edema, anxiety, headache, abdominal pain, constipation, hypophosphatemia, hyperbilirubinemia, mucositis, sepsis; anaphylaxis, hemolysis, methemoglobinemia.
Elitek Clinical Trials
Elitek Patient Counseling